Telix Pharmaceuticals Limited reported unaudited group revenue of $206 million in Q3 2025, a 53% increase from the previous year. Revenue guidance for FY 2025 has been raised to $800 million to $820 million. Gozellix® is now fully reimbursed by CMS in the U.S., with Illuccix® approved in 19 European markets and the UK.
Telix’s prostate cancer therapy candidate, TLX591, has closed enrollment for Part 1 of the ProstACT Global Phase 3 trial. TLX250 has received ethics approval for a pivotal trial in advanced metastatic clear cell renal cell carcinoma. Other therapeutic candidates are progressing in clinical trials.
In the Precision Medicine business, Telix’s PSMA imaging products are making strides in the market. Gozellix® has achieved full reimbursement status in the U.S., while Illuccix® is being rolled out in European markets. The BiPASS™ study aims to reduce invasive biopsies for prostate cancer diagnosis.
Telix is also advancing its Pixclara® and Zircaix® products for brain and kidney cancer imaging, respectively. Manufacturing facilities in Australia and Japan have received radiation licenses, positioning Telix for operational readiness.
Telix successfully completed its final royalty payment to ANMI, reflecting strong sales performance. The company has increased its FY 2025 revenue guidance and confirmed R&D expenditure expectations. Investors are cautioned about the various factors that could impact Telix’s financial forecasts.
Telix Pharmaceuticals Limited is a biopharmaceutical company focusing on therapeutic and diagnostic radiopharmaceuticals. With operations in multiple countries, Telix is developing products to address unmet medical needs. Key products like Illuccix® and Gozellix® have received FDA approval and are making strides in the market.
For further information, investors can visit Telix’s website or follow the company on social media platforms. The company’s legal notices emphasize caution regarding forward-looking statements and highlight the risks associated with investment decisions in Telix Pharmaceuticals Limited. Trademarks and trade names mentioned in the announcement belong to Telix or their respective owners.
Read more at GlobeNewswire: Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded